Beyond Biotech - the podcast from Labiotech

There is a constant risk of severe, potentially life-threatening allergic reactions for individuals with peanut allergies, which leads to significant physical, social, and emotional burdens.IgGenix, a clinical-stage immunology biotechnology company, recently announced the first patient dosed in its phase 1 trial evaluating IGNX001, a novel monoclonal antibody-based therapeutic, for peanut allergy. Designed to neutralize the most clinically important peanut allergens and epitopes, IGNX001 combats peanut allergies by blocking the allergic cascade and reducing risk of anaphylaxis.Should IGNX001 prove successful, it will provide a promising solution for peanut allergies and pave the way for IgGenix's technology to be applied to other types of food allergies and allergic diseases.Our guest on the podcast this week is Jessica Grossman, chief executive officer of IgGenix.01:14-02:51: About IgGenix02:51-06:30: About peanut allergy06:30-07:31: Are allergies on the rise?07:31-08:46: Are allergy responses similar?08:46-10:13: The problems with treating allergies10:13-13:53: Current treatments for peanut allergy13:53-15:45: The challenges of developing drugs to treat allergies15:45-16:54: Overcoming the placebo effect16:54-18:18: Are other companies working on allergy treatments?18:18-21:32: IgGenix’s SEQ SIFTER platform21:32-24:20: About IgGenix’s IGNX00124:20-24:42: Repeat doses24:42-26:19: Could peanut allergy sufferers eat peanuts?26:19-27:46: Can the technology be adapted to treat other allergies?27:46-28:56: Are there variations in the treatment of different allergies?28:56-29:35: Treatments for other diseases29:35-30:23: The future for people with allergiesInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

Adam Marťák, founder and CEO of ambiom—a life science advisory firm in Bratislava—shares insights into Eastern Europe's biotech scene. He discusses the challenges startups face, from navigating complex regulations to securing funding. Marťák explains different biotech valuation methods, emphasizing that early-stage companies offer greater upside potential for investors. The conversation also explores how pipeline composition affects success rates and touches on the increasing influence of AI in drug discovery, transforming the investment landscape.

Biological control company Oxitec recently launched Sparks, a new platform designed to rapidly scale Wolbachia replacement technology to take on dengue fever.Backed by a multi-million-dollar investment from the Gates Foundation, Sparks adds to Oxitec’s Aedes aegypti technology, called Friendly, which is taking on dengue fever in Brazil. With mosquito-borne diseases on the rise, Oxitec’s Friendly mosquitoes are designed to suppress populations of disease-spreading mosquitoes and, in turn, reduce biting and the threat of disease transmission. Wolbachia-carrying mosquitoes are designed to spread Wolbachia bacteria into the local mosquito population to limit the ability of the remaining infected mosquito population to transmit dengue. The platforms are designed for specific settings and intervention types, and provide options for governments and communities seeking suppression, replacement or hybrid approaches using both.Our guest on the podcast this week is the CEO of Oxitec, Grey Frandsen.00:56-02:12: About Oxitec02:12-05:54: The state of mosquito-borne diseases05:54-07:09: The effect of climate change07:09-08:29: Moving into more developed countries08:29-10:27: Wolbachia replacement technology10:27-12:53: The Sparks program12:53-13:46: Other companies’ approaches13:46-15:00: World Mosquito Program15:00-15:30: Establishing timelines15:30-17:20: The effect on the environment17:20-18:54: Could adaptation render the technology useless?18:54-20:52: Are the Sparks and Friendly programs being used together?20:52-21:57: Do the technologies work differently on different species?21:57-26:28: How to determine rollout conditions26:28-27:19: Are repeat interventions needed?27:19-30:32: Are there limitations based on cost or politics?30:32-33:11: Are the technologies applicable to other problems?33:11-35:08: Is there anything else in Oxitec’s pipeline?Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

Immunology is a key area in biotech and biopharma, both in terms of R&D and sales.However, according to UK-headquartered Greywolf Therapeutics, the industry has only focused on two-thirds of the puzzle.To have an immunological effect, you must activate the body’s T cells, which cells requires a chain of three key signals. The first is antigen recognition, i.e. the initial detection of a cell by a T-cell. The second is the co-stimulation of non-antigen presenting molecules, which enhances the immune response​. The final step is cytokine-mediated differentiation and expansion, which guides how T-cells target threats. ​Companies have focused on the second two signals, with signal 2 most commonly seen in therapies such as checkpoint inhibitors and monoclonal antibodies. Signal 3, on the other hand, can be primarily seen in therapies for autoimmune disorders, such as anti-TNF and JAK inhibitors.Greywolf Therapeutics is the first company to explore changing signal 1. The company says focusing on signal 1 applies in three key therapeutic areas: oncology, autoimmunity and virology. Greywolf’s first candidate has delivered strong results during its ongoing phase I/II trial in oncology, therefore demonstrating proof-of-mechanism and target engagement, with its next candidate well-progressed in preclinical development in autoimmunity.To tell us more about the company and its work is Pete Joyce, CEO and co-founder of Greywolf Therapeutics.01:19-04:12: About Greywolf Therapeutics04:12-04:51: The origins of the name04:51-06:52: The three ‘signals’ of the mechanics of immunological responses06:52-08:31: Treatments associated with each signal08:31-10:09: Why is step 1 important, and why has it not been investigated for treatments?10:09-11:28: What areas of disease is this applicable to?11:28-12:19: How do you inhibit ERAP?12:19-14:01: Greywolf Therapeutics’ candidates14:01-15:11: How is this an advance on current treatments?15:11-16:05: What is success for patients?16:05-17:20: How does the stage of disease affect treatment?17:20-18:09: Are other companies looking into antigen modulation? 18:09-19:47: Has this led to investment opportunities?19:47-21:15: Next steps21:15-21:55: Do you anticipate more interest in this space?21:55-23:21: Attending events Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

The Bill & Melinda Gates Medical Research Institute (Gates MRI) is a non-profit medical research organization dedicated to the development and effective use of products like drugs, vaccines and monoclonal antibodies to address substantial global health concerns, for which investment incentives are limited, including malaria, tuberculosis, diarrheal diseases, and diseases that impact maternal, newborn, and child health.This week, our guest is Dr Claire Wagner, head of corporate strategy and market access at Gates MRI.Wagner has dedicated her life to global health. Her early years working in West Africa and East Africa – including five years working with the Rwanda Ministry of Health – were formative experiences for her. She helped document health sector outcomes in Rwanda and had a front row seat to the progress the country was making at the time, which led to her pursuing and obtaining an MD and MBA from Harvard.Her experiences led to her becoming one of the early employees of the Gates MRI, where she is on the executive leadership team and leads the institute's global access strategy as well as related engagement with commercial partners, financial institutions and multilaterals.She tackles the challenge of paving the way for the drugs, biologics and vaccines that the Gates MRI is developing – if they are successful in clinical trials – to be affordable and accessible to the people in low- and middle-income countries who would benefit most. In March 2024 the Gates MRI launched a phase 3 clinical trial for a tuberculosis vaccine candidate, and market access for this candidate is a top priority for Wagner.01:51-04:47: Background on Dr Claire Wagner04:47-06:24: Work in Rwanda06:24-08:40: Gates MRI08:40-12:50: Progress at Gates MRI12:50-14:06: Gates MRI R&D priorities14:06-16:26: The differences between Gates MRI and traditional biotechs16:26-18:40: Gates MRI partnerships18:40-22:52: The inequality of developing drug treatments22:52-25:45: Return on investment25:45-27:01: Did COVID increase global awareness?27:01-27:44: Other companies working on treatments27:44-31:48: Gates MRI pipeline and clinical trials31:48-34:51: Working on tuberculosis34:51-36:00: Treatment mode of action36:00-37:25: Future work at Gates MRIInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

This week, we are taking a look at an important subject, and that is women working as CEOs, or other senior roles, in the biotech space. Kate Yen is the CEO of oncology biotech Auron Therapeutics, and she has spent her entire career in science. Auron is working on the next generation of targeted cancer therapies by identifying and inhibiting the oncogenic cell states of cancer. Auron’s AURIGIN platform uses AI and machine learning to compare normal cell states with cancerous cell states to identify novel cancer targets, optimal development models, and biomarkers to guide patient selection. Auron is building a pipeline of small molecule targeted therapies, led by AUTX-703, which is being developed for the treatment of solid tumors and hematologic malignancies, including acute myeloid leukemia.02:16-07:44: About Kate Yen and Auron Therapeutics07:44-09:09: The challenges of setting up a company09:09-11:56: Auron Therapeutics’ lead candidate11:56-12:52: The rest of the pipeline12:52-13:29: Auron timeline13:29-15:01: Are there specific challenges being a female biotech CEO?15:01-15:49: Is there support for women in biotech beyond the CEO level?15:49-16:51: Helping others16:51-17:41: Challenges in the boardroom17:41-18:40: Diversity in biotech19:40-21:03: Changing mindsets22:05-22:59: Being a role model22:59-24:43: Attracting women from outside hubs25:42-27:28: Diversity and education27:28-31:31: The importance of AI31:31-32:34: The evolution of AuronInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletterThis week’s podcast is sponsored by Cryoport Systems, the global leader in comprehensive temperature-controlled supply chain solutions, is proud to introduce IntegriCell™ to preserve the future of medicine. IntegriCell™ cryopreservation services provide an integrated, end-to-end solution to ensure the highest quality, consistency, and viability of manufacture-ready, cryopreserved leukopaks for cell therapies. IntegriCell™ enables seamless, efficient, and reliable cryopreservation services combined with end-to-end supply chain solutions to support the treatment of patients worldwide. For more information, visit Cryoport.com.

Sitryx Therapeutics is a private UK biopharma company founded in 2018. It is a leader in the field of immunometabolism, an area of immunology that looks to rebalance the immune system to achieve sustained disease remission in autoimmune and inflammatory diseases. Sitryx already has big pharma validation following a deal with Eli Lilly in 2020 worth in excess of $1 billion and is focused on advancing its pipeline of potentially first- and best-in-class therapies, which could address a wide range of chronic conditions, including SYX-5219 for atopic dermatitis.The company has a broad pipeline of small molecules against novel targets in major autoimmune indications with high unmet need.To talk about immunometabolism, our guest on the podcast this week is CEO of Sitryx Therapeutics, Iain Kilty.00:52-01:48: About Sitryx01:48-02:32: What is immunometabolism?02:32-05:01: Approaches to address autoimmune and inflammatory diseases05:01-06:46: Drug development06:46-08:29: What is Sitryx’s approach?08:29-11:02: Finding diseases to treat11:02-13:09: About SYX-521913:09-16:08: Inflammatory response16:08-18:40: About SYX-1042 and Eli Lilly18:40-19:54: Mode of delivery19:54-20:49: The Sitryx pipeline20:49-22:08: Research on immune cell function and other companies’ work22:08-23:53: Increased interest in the field23:53-25:06: More investment and deals25:06-26:30: Future treatments of autoimmune and inflammatory diseases26:30-27:59: The future of immunometabolism27:59-29:26: Sitryx’s goalsInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

LinkGevity, founded by two sisters, is developing anti-necrotic technologies, especially for application in kidney disease.Carina Kern is the CEO of the company, while Serena Kern-Libera is the chief operating officer. After reading an article about how space-travel is especially damaging to the kidneys, they applied for a place on the inaugural NASA Space-H Accelerator program, and how medicine can support human deep-space missions.LinkGevity was selected for the program, which is in its inaugural year. LinkGevity was selected as its research has uncovered technology with significant potential to minimize the health and performance risks in human spaceflight.LinkGevity’s anti-necrotics applications cover four major areas: organoid preservation and growth; cryopreservation; organ growth and preservation; and kidney protection.LinkGevity’s novel proprietary Blueprint Theory of Aging, developed by Kern, offers a multi-disciplinary framework for understanding the development of age-related diseases and deterioration. The theory enables the company’s AI to accurately identify and target key biological pathways involved in aging and deterioration, with necrosis being one of the most critical processes addressed.To talk about the company’s technology, and its application to space, we had a conversation with Carina Kern and Serena Kern-Libera.01:48-05:45: About LinkGevity05:45-06:39: What is the goal for LinkGevity?06:39-09:07: Is early intervention important?09:07-11:10: What is the Blueprint Theory of Aging, and how do you identify and target key biological pathways involved in aging and deterioration?11:10-13:51: Applying the theory13:51-15:03: Necrosis and LinkGevity’s Anti-Necrotic technology15:03-18:37: Blocking necrosis and treating disease18:37-19:06: Drug delivery19:06-20:54: The importance of AI20:54-24:43: Connecting LinkGevity’s work with space24:43-26:24: The SPACE-H program27:18-28:13: Other biotech involvement in the program28:13-30:13:  LinkGevity’s presentation at Space-Comm30:13-31:00: Keeping space medicine simple31:00-32:18: The future for LinkGevity32:18-33:14: LinkGevity’s timescale33:14-33:47: Clinical trials33:47-34:53: LinkGevity’s future space work34:53-35:30: Different space opportunities35:30-38:12: LinkGevity fundingInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

Today, gene therapy is at an exciting inflection point as the industry moves beyond the first generation of these therapies. However, challenges and barriers remain in bringing gene therapies to market, particularly as they expand into more prevalent diseases. Spur Therapeutics is a clinical-stage biotech company dedicated to developing next generation gene therapies for people living with chronic, debilitating diseases. Its lead candidate, FLT201, is an AAV gene therapy for Gaucher disease that is poised to enter phase 3 development in 2025.This week, we have a conversation with Michael Parini, CEO of Spur Therapeutics, about the future of gene therapy.01:56-04:01: About Spur Therapeutics04:01-06:49: Where is the gene therapy field at currently?06:49-10:44: The biggest challenges for gene therapies, and potential solutions10:44-13:21: What is the next generation of gene therapy?13:21-18:08: How can gene therapy be used to take on more diseases? How can it be cheaper?18:08-19:14: Are other companies working on next-generation gene therapies?19:14-21:07: What is Gaucher disease?21:07-22:32: How are you tackling Gaucher disease?22:32-26:07: What is the measure of success?26:07-28:18: About adrenomyeloneuropathy28:18-29:32: Upcoming approvals in gene therapy29:32-31:40: How quickly is gene therapy evolving?This podcast is sponsored by Vetter, a globally leading CDMO, with over 70 years of experience as a responsible, independent family business. Driven by more than 6,600 employees worldwide, Vetter provides life-saving injectable drug products to the patients that rely on them most. Vetter partners with its customers throughout the entire product lifecycle, starting in the early phase of drug development with comprehensive expertise and support in clinical manufacturing for in-human trial material. For more information, visit vetter-pharma.comInterested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated by subscribing to our newsletter

Antibody-drug conjugates have been an area of great interest in the oncology space in recent years, with a record rate of FDA approvals and dealmaking activity. However balancing efficacy and off-site toxicity has remained a challenge.Some biopharma companies are investing in what they hope will be the next-generation approach to ADCs – bispecific ADCs. More than a dozen early-stage clinical trials are evaluating whether adding a second targeting functionality can improve the preciseness of ADCs’ tumor-targeting, as well as potentially overcome the challenge of heterogeneity in solid tumor target expression. Bispecific ADCs have been a hot area for dealmaking over the past year, including BMS’ $8.4 billion purchase of a bispecific ADC candidate in December, a $690 million deal between Biotheus and Hansoh this spring, and the recently announced $325 million deal between Prague-based SOTIO Biotech and Biocytogen.SOTIO’s most advanced ADC, SOT102, is now in a phase 1/2 clinical study in the U.S. and Europe. To talk about biotechs in Czechia, and bispecific ADCs, our conversation this week is with Radek Špíšek, CEO of SOTIO.01:22-03:17: About SOTIO03:17-06:12: Are there many biotech or biopharma companies in Prague? 06:12-08:16: Are there any challenges or opportunities being in Prague?08:16-13:21: What are bispecific ADCs and how do they differ from regular ADCs?13:21-15:37: Are there any challenges using bispecific ADCs?15:37-17:07: What are the benefits of bispecific ADCs?17:07-18:40: Do bispecific ADCs address the challenge of balancing efficacy and off-site toxicity?18:40-19:42: Why are bispecific ADCs such a hot topic?19:42-21:35: Deals involving bispecific ADCs, and SOTIO’s partnership with Biocytogen21:35-24:15: What is SOT102?24:15-26:41: What else is in SOTIO’s pipeline?26:41-27:47: What is the future for bispecific ADCs? 27:47-29:01: What does this mean for patients?Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here! Stay updated of the latest biotech news by subscribing to our newsletter